Back to top
more

The Medicines Company (MDCO)

(Delayed Data from NSDQ)

$31.89 USD

31.89
912,624

+0.61 (1.95%)

Updated May 3, 2019 04:00 PM ET

After-Market: $31.90 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Medicines Co. (MDCO) Reports Q2 Loss, Misses Revenue Estimates

Medicines Co. (MDCO) delivered earnings and revenue surprises of 1.56% and -78.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

    Medicines Company's Inclisiran Studies to Continue Unmodified

    The Medicines Company (MDCO) announces that Independent Data Monitoring Committee has recommended that the ongoing phase III studies of its candidate, inclisiran, will continue without modification.

      Alnylam Reports Positive Data on Lumasiran in Renal Disease

      Alnylam (ALNY) announces positive results from the ongoing study on lumasiran in Primary Hyperoxaluria Type 1 (PH1) patients.

        Medicines Company (MDCO) Up 11.4% Since Earnings Report: Can It Continue?

        Medicines Company (MDCO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

          Ekta Bagri headshot

          Hospital Product Sales Drive Mallinckrodt (MNK) Q1 Earnings

          Mallinckrodt's earnings and sales beat in the first quarter boosted investor sentiment as hospital products sales revived.

            Alnylam's (ALNY) Q1 Loss Wider than Expected, Sales Miss

            Alnylam (ALNY) incurs narrower-than-expected loss and missed revenue estimates in Q1. With several pipeline related events lined up and potential approval for patisiran, we expect investor focus to remain on the related updates.

              Medicines Company's (MDCO) Q1 Loss Widens, Revenues Tank Y/Y

              The Medicines Company (MDCO) incurs wider-than-expected loss in the first quarter of 2018. The top line also missed estimates and declined year over year.

                The Medicines Company (MDCO) Up 4.8% Since Earnings Report: Can It Continue?

                The Medicines Company (MDCO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                  Mallinckrodt (MNK) Up on Earnings and Revenues Beat in Q4

                  Mallinckrodt (MNK) shares gained as the company beat both earnings and revenue estimates in the fourth quarter as Inomax sales revived somewhat.

                    Medicines Company (MDCO) Reports Q4 Loss, Revenues Slump Y/Y

                    Medicines Company (MDCO) incurs wider-than-expected loss in the fourth quarter of 2017. Moreover, the top line declines year over year on low Angiomax sales.

                      Alnylam's (ALNY) Q4 Earnings and Revenues Top Estimates

                      Alnylam Pharmaceuticals (ALNY) reports narrower-than-expected loss and beats sales estimates in the fourth quarter of 2017.

                        What Bargain Hunting? Bet on 6 Stocks With Rising P/E

                        Inside the top-ranked stocks that have been exhibiting rising P/E ratios.

                          Is the Options Market Predicting a Spike in Medicines Company (MDCO) Stock?

                          Investors in Medicines Company (MDCO) need to pay close attention to the stock based on moves in the options market lately.

                            Mallinckrodt (MNK) to Sell Recothrom and Preveleak to Baxter

                            Mallinckrodt's (MNK) strategy to streamline its business to evolve as a top-performing specialty pharmaceutical company has led the company to enter into an agreement to sell Recothrom and Preveleak to Baxter.

                              The Zacks Analyst Blog Highlights: XOMA, Exelixis, Emergent BioSolutions and Medicines

                              The Zacks Analyst Blog Highlights: XOMA, Exelixis, Emergent BioSolutions and Medicines

                                4 Biotech Stocks to Watch in the New Year

                                We take a look at four companies with a favorable Zacks Rank that performed well in 2017 and are likely to continue on the growth path in 2018 as well.

                                  Can Sucampo Acquisition Turn Mallinckrodt Stock Around?

                                  Mallinckrodt (MNK) faced challenging business conditions in 2017 and the company is now looking to revive business with the recently announced Sucampo acquisition.

                                    Is the Options Market Predicting a Spike in The Medicines Company (MDCO) Stock?

                                    Surging implied volatility makes The Medicines Company (MDCO) stock lucrative to the option traders.

                                      Why is Alnylam's (ALNY) Stock Up More Than 200% This Year?

                                      Alnylam's (ALNY) share price has increased year to date based on impressive progress of its pipeline candidates.

                                        Medicines Company to Sell Infectious Disease Unit to Melinta

                                        The Medicine Company (MDCO) has signed an agreement with Melinta to sell its infectious disease unit in a cash and stock transaction.

                                          Mallinckrodt (MNK) Down 55% Year to Date: What Lies Ahead?

                                          Mallinckrodt plc (MNK)'s stock lost 55% in the year so far due to ongoing investigations and weakness in Acthar and Inomax.

                                            Mallinckrodt (MNK) Earnings, Sales Decline Y/Y in Q3

                                            Mallinckrodt (MNK) sales and earnings declined in the third-quarter due to volume Acthar declines.

                                              Alnylam's (ALNY) Q3 Earnings, Revenues Miss Estimates

                                              Alnylam Pharmaceuticals (ALNY) incurred wider than expected loss and missed sales estimates in the third quarter of 2017.

                                                Implied Volatility Surging for The Medicines Company (MDCO) Stock Options

                                                The Medicines Company (MDCO) needs investors to pay close attention to the stock based on moves in the options market lately.

                                                  Medicines Company (MDCO) Reports Q3 Loss, Revenues Miss

                                                  The Medicines Company (MDCO) incurs loss in the third quarter of 2017. The top line decreases year over year due to low Angiomax sales.